Auro Pharmacies, Inc., La Habra, CA

Is Auro Pharmacies, Inc. registered with the FDA as a 503B outsourcing facility?

No matching record found in FDA’s registered outsourcing facility list (updated Nov 6, 2026) on Nov 15, 2026, searching by name and location. FDA’s compounding inspections and actions page labels it a 503A facility, with FDA’s note “Out of business”.

Does Auro Pharmacies, Inc. hold a California pharmacy license?

No license with this exact name and city was found in the California State Board of Pharmacy file dated Nov 6, 2026. A pharmacy can hold its license under a different legal name, so this is not a finding that it is unlicensed. The file lists current licenses only, not revoked, surrendered or cancelled ones. The Colorado State Board of Pharmacy also lists nonresident license OSP 5808 for Auro Pharmacies, Inc. DBA Central Drugs, La Habra, CA, status Active, as of Nov 15, 2026. The Illinois Department of Financial and Professional Regulation also lists nonresident license 054018330 for AURO PHARMACIES INC, LA HABRA, CA, status ACTIVE, as of Nov 13, 2026. The Connecticut Department of Consumer Protection also lists nonresident license PCN.0002978 for AURO PHARMACIES INC (dba CENTRAL DRUGS), LA HABRA, CA, status ACTIVE (CURRENT), as of Nov 15, 2026.

Has Auro Pharmacies, Inc. had a state board action or FDA letter?

FDA letters: record found. FDA’s compounding inspections and actions page, current as of Oct 22, 2026, lists 1 warning letter (Jun 3, 2020), 1 state referral letter (Apr 6, 2023) and 1 FMD-145 letter (Apr 11, 2023) for Auro Pharmacies, Inc. State board actions: record found. The California State Board of Pharmacy’s posted disciplinary decisions on facility licenses lists “Through a disciplinary action of the Board, the license is granted and subject to a public reproval” dated Nov 1, 2018, case SI 6203 on license OSF 123. The Colorado State Board of Pharmacy’s license dataset also lists 2 actions: “CLS Stipulation” dated Jun 5, 2014, case 2014-1355 on nonresident license OSP 5808 and “CLS Stipulation” dated Jan 13, 2011, case 2011-2203 on nonresident license OSP 5808. The Illinois Department of Financial and Professional Regulation’s license dataset also lists 2 actions: “Fine” dated Jul 29, 2021, case 2018009679 on nonresident license 054018330 and “Probation” dated Jul 29, 2021, case 2018009679 on nonresident license 054018330. The state referral and handoff letters above are FDA’s letters to the state, not board actions.

FDA registers 503B outsourcing facilities; state boards of pharmacy license pharmacies, including 503A compounding pharmacies, and keep their own disciplinary records. Neither FDA list says which drugs a pharmacy makes.

Names in FDA records
Auro Pharmacies, Inc.
Location
La Habra, CA
Type as FDA labels it
503A
FDA’s note
Out of business
FDA 503B list
No matching record found
Form 483s on FDA’s actions page
2
Warning letters on FDA’s actions page
1
Latest action on that page
Apr 11, 2023
FDA Data Dashboard inspections
5 inspections: 4 OAI, 1 VAI; 6 published Form 483s
Form 483 text on this page
7 Form 483s, 77 observations
State board records
No exact match

FDA inspections and letters

FDA’s compounding inspections and actions page (current as of Oct 22, 2026) lists this pharmacy as Auro Pharmacies, Inc., a 503A facility, with 5 dated actions.

Document
Apr 11, 2023FMD-145 letterFMD-145 Letter Issued 04/11/2023Not linked by FDA
Apr 6, 2023State referral letterReferral Letter to the California State Board of Pharmacy Issued 04/06/2023fda.gov
Aug 12, 2022Form 483483 Issued 08/12/2022FDA copy (archived)
Jun 3, 2020Warning letterWarning Letter (06/03/2020)FDA copy (archived)
Oct 18, 2019Form 483483 Issued 10/18/2019FDA copy (archived)

A Form 483 lists investigator observations, not a final FDA determination. A warning letter states FDA’s view when it was issued, not a court finding; any close-out letter FDA lists is a row of its own. An untitled or FMD-145 letter states FDA’s view when it was issued.

FDA inspection classifications and published Form 483s

The FDA Data Dashboard, read Nov 15, 2026, lists Auro Pharmacies, Inc., La Habra, CA (FEI number 3011893599); Auro Pharmacies, Inc, La Habra, CA (FEI number 3012228279), matched to this page by exact name, city and state. It lists 5 inspections: 4 OAI, 1 VAI at those sites, newest first, with FDA’s classification as worded on the dashboard. Dashboard firm profile (FEI 3011893599). Dashboard firm profile (FEI 3012228279).

Inspection endedClassificationProject area and product typeFEIInspection ID
Aug 12, 2022Voluntary Action Indicated (VAI)Drug Quality Assurance (Drugs)30118935991177654
Oct 18, 2019Official Action Indicated (OAI)Drug Quality Assurance (Drugs)30122282791107187
Aug 2, 2018Official Action Indicated (OAI)Drug Quality Assurance (Drugs)30118935991061744
Jun 29, 2017Official Action Indicated (OAI)Drug Quality Assurance (Drugs)30122282791016245
Nov 5, 2015Official Action Indicated (OAI)Drug Quality Assurance (Drugs)3011893599948676

Form 483s FDA has published for these sites

FDA classifies each inspection when it is closed: No Action Indicated (NAI) means no objectionable conditions were found or they did not justify further action; Voluntary Action Indicated (VAI) means objectionable conditions were found but FDA is not prepared to take or recommend regulatory action; Official Action Indicated (OAI) means FDA recommended regulatory or administrative action. A classification is FDA’s, not a finding by this site. The dashboard lists inspections once FDA has classified them, from fiscal year 2009 on, so a recent inspection may not appear yet.

Form 483 observations

A Form 483 lists an FDA investigator’s observations at the end of an inspection. It is not a final FDA determination. In FDA’s words: “The FDA Form 483 does not constitute a final Agency determination of whether any condition is in violation of the FD&C Act or any of its relevant regulations.” (FDA Form 483 FAQ). The firm may have answered or corrected these points; a response is not shown here unless FDA lists one.

FDA’s published Form 483s for this site have 77 numbered observations in all, across 7 inspections ending Sep 22, 2015 to Aug 12, 2022. Each observation is quoted from the PDF as FDA numbered it, with long ones cut and linked to the full form. Names of people on the form are not shown. What a Form 483 is; all 483s in this index.

Inspection Aug 4, 2022 to Aug 12, 2022: 2 observations

Firm on the cover
, 520 W La Habra Blvd Auro Pharmaci es, Inc., CODE
FEI number
3011893599
Establishment type on the cover
La Habra, CA 90631 Compounding Pharmacy
FDA district office on the cover
Irvine, CA 92612
Matched to this page by
FEI number on the cover; linked from actions page, Data Dashboard
FDA document
Read the full 483 (PDF on fda.gov)

This 483 is a scanned image. The text below is the PDF’s own text layer, which can misread characters; the PDF is the record.

Observation 1

You produced hazardous drugs without providing adequate containment or cleaning of and work surfaces to prevent cross-contamination.

Specifically, an accumulation of what appeared to be white powder was observed in areas on your <Redacted

B4> hoods. On 8/4/2022, the area under the HEPA filters and the bolts on the front shield of two ho ods h ad the apparent powder accumulation. The hoods are used for hazardous drug encapsulation during compounding ope rations and ide ntified as <R edacted B4> and <Redacted B4>. <Redacted B4> hazardous (including Progesterone, Estradiol, and Anastrozole) lots were manufactured on 8/4/2022.

Observation 2

Non-microbial contamination was observed in your production area.

Specifically, an accumulation of what appeared to be white powder was observed in areas on your <Redacted B

4> hoods. On 8/4/2022, the area under the HEPA filters and the bolts on the front shield of two hood

s

had the appare nt powder acc

u mulation. The hoods are used for non-hazardous drug encapsulation during compounding ope rations and identified as < Redacted B4> and <Redacted B4>. <Redacted B4> non-hazardous (including Pregnenolone/DHEA, T 3, T4/T3, and Naltrexone) capsule lots were manufactured on 8/4/202 2.

Inspection Sep 17, 2019 to Oct 18, 2019: 11 observations

Firm on the cover
Auro Pharmacies Inc, 511 S Harbor Blvd Ste F, La Habra, CA 90631-9375
FEI number
3012228279
Establishment type on the cover
Outsourcing Facility
FDA district office on the cover
19701 Fairchild Irvine, CA 92612-2445
Matched to this page by
FEI number on the cover; linked from actions page
FDA document
Read the full 483 (Internet Archive copy FDA links)

Observation 1

Aseptic processing areas are deficient regarding the system for monitoring environmental conditions.

Specifically, the ISO 5 classified hoods used for aseptic mixing/filling and <Redacted B4> are not adequately designed or maintained for the operations they are used for.

a) The firm has <Redacted B4> hoods <Redacted B4> ) used for mixing and a separate <Redacted B4> hoods <Redacted B4>) used for filling operations. The hoods are not adequate for reasons including, but not limited to, the following:

I.

All the filling hoods and four of the <Redacted B4> mixing hoods (<Redacted B4>) have cracks in the left and right side panels.

II. The ISO 5 hoods except <Redacted B4> are not designed in a way that allows cleaning of all surfaces. The light in the hoods reside in an open exposed crevice <Redacted B4> closest to the operator. The area is difficult to clean without inserting the cleaner's bodies into the hood. On 9/18/2019, I observed hood <Redacted B4> had dark material in the crevice. On 9/25/201-8-2., I observed the remaining hoods, with the exemption of <Redacted B4> I also had dark material in the crevice.

III. ...

Read the full 483 (Internet Archive copy FDA links)

Observation 2

There is a failure to thoroughly review any unexplained discrepancy and the failure of a batch or any of its components to meet any of its specifications whether or not the batch has been already distributed.

Specifically,

Your firm either failed to initiate or failed to adequately investigate out-of-specification (OOS) including environmental monitoring (EM) failures and sterility failures. The firm performs investigations under OOS and does not have a separate procedure for investigations. Examples include, but are not limited to the following:

a) Your firm did not investigate a viable EM failure occurring during the certification of the ISO 5 hood <Redacted B4>), performed from May 29th to June 11th , 2018. During this certification the ISO 5 hood <Redacted B4> which is utilized for sterile filling operations, had fail results for viabl.e airborne EM results and viable surface EM results. The specification has an action limit of <Redacted B4> CFU. The result was 1 CFU for each EM failure. The airborne microbial was identified as a gram-positive cocci and the surface microbial was not identified. No speciation was determined for either microbial. ...

Read the full 483 (Internet Archive copy FDA links)

Observation 3

Laboratory controls do not include the establishment of scientifically sound and appropriate specifications and sampling plans designed to assure that in-process materials and drug products conform to appropriate standards of identity, strength, quality and purity.

AM ENDMENT2

Specifically, the non-viable particulate data, viable particulate data and finished product visual inspection are not adequate to assure in-process materials or drug products conform to standards of quality. For Example:

a) Non-viable particulate (NVP) data. is not collected, stored, or reviewed adequately to assure in-process materials or drug products conform to standards of quality. NVP data is collected <Redacted B4> of all sterile-drug products. The data is collected <Redacted B4> however, only an average read out is provided. No alarms occur for individual reading that are out-of-specification. The raw data is not backed-up or stored and can not be reviewed later. The review of the data. is only the average throughout the entire filling process.

b) Your firm's 100% visual inspection is performed <Redacted B4> with operators who have not been qualified to detect a standardized particulate size. ...

Read the full 483 (Internet Archive copy FDA links)

Observation 4

The statistical quality control criteria fail to include appropriate acceptance levels and rejection levels.

Specifically,

AMENDMENT2

Your firm failed to establish acceptance criteria for the sampling and testing conducted by the quality control unit that are adequate to assure that batches of drug products meet each appropriate statistical quality control criteria as a condition for their approval and release.

a) Your firm does not review the rejection level of sterile finished drug products. There is no statistical limit placed on the number of products that can be rejected during review of finished drug products. Two of the ten batches (Lot 190613@2 of Pyridoxal-5-Phosphate and 190708@2 of Calcium Gluconate) I reviewed had 10% or greater vials removed for paii iculate contamination occurring. These results were not flagged or investigated.

b) ¥eH¼· HRB sees set 13edeRB aei.11-te ai1· 1Heaitefiag et: :i.tiaele 13~iealates eH¼·iag J3feeaetiea.

lw!ieele 13aHie'l¼l~es aie meaitet'ee 'l¼siag a. se~.hag 13late 8:H¼·iag f3t'eeaetiea. He•.1,ie• .. ef, e•.•ieeaee dtat the ia he'l¼se geaenitea setthag 13l~es ma.iata.ia g1·e•<1r:th f3t'emetiea a~t'il'l'l¼tes feUe1,1fiag 'l¼f3 te ...

Read the full 483 (Internet Archive copy FDA links)

Observation 5

Procedures designed to prevent microbiological contamination of drug products purporiing to be sterile did not include adequate validation of the aseptic process.

Specifically,

a) Your firm did not perform media fills under actual conditions or at intervals in all hoods. The firm has not conducted media fills for ISO 5 hood <Redacted B4> in 2019.

b) The cleaning wands used to clean the hoods has apparent degradation or filth contamination. The material at the end of the wand is discolored and has orange spots on it. These wands reside inside of the hood.

c) Currently, there is no program developed to evaluate <Redacted B4> product compatibility. The firm's <Redacted B4> have not been evaluated for product compatibility. According to the <Redacted B4> log the current pharmaceutical grade <Redacted B4> usage occurred on 7/31/2018. Prior to this date your firm used non-pharmaceutical grade <Redacted B4> .

AM ENDMENT2

Observation 6

There was a failure to handle and store drug product containers and closures at all times in a manner to prevent contamination.

Specifically, your firm stores vials utilized as container/closures in an ISO 8 classified room for up to 21 days without adequate hold time evidence to ensure they remain sterile. Following sterilization <Redacted B4> vials are held in non-air tight wrapping in an ISO 8 room for up to 21 days prior to use. The vials are used as container closures for all products. The hold time study supporting this hold-time does not include the number of vials tested or the testing method utilized for testing.

Observation 7

You used a non-pharmaceutical grade component in the formulation of a drug product.

Specifically, Your firm used non-pharmaceutical grade API to produce at least two finished drug products.

a) Your firm produces sterile injectable drug product with dietary supplement grade Glutathione. Glutathione is used to produce drug products including Glutathione 200mg/ml MDV and Glutathione 200mg/ml SDV. Glutathione ingredient is received from one supplier and the certificate of analysis from that supplier indicates that the API meets the monograph for dietary supplements. Your firm has released at least <Redacted B4> lots of Glutathione since January 1st, 2019.

b) Your firm produces sterile drug product with dietary supplement grade Choline Chloride. Choline Chloride is used to produces drug products including MIC 25/50/50 mg/ml. Choline Gaklum Chloride is received from one supplier and the certificate of analysis from that supplier indicates that the API meets the monograph for dietary supplements. Your firm has released at least <Redacted B4> lots of MIC 25/50/50 mg/ml since January 1st , 2019.

Observation 8

The quality control unit lacks authority to fully investigate errors that have occuned.

AMENDM ENT2

Specifically, Your quality unit has not acted adequately in its responsibilities. For example:

Microbial out-of-specifications occurring in production areas during hood recertifications occurring from May 29th to June 11th nor 6/12/2018 were not identified or investigated.

Investigations into microbial contamination documented in OOS 18-0016 and OOS 19-004 have not been conducted adequately.

Evaluation of equipment such as <Redacted B4> and container closures have not been evaluated adequately.

The quality unit released drug products made with non-pharmaceutical grade active pharmaceutical ingredients including Dietary Supplement grade Glutathione and Choline Chloride.

Observation 9

Routine calibration and checking of equipment is not performed according to a written program designed to assure proper performance.

Specifically, Your firm's <Redacted B4> has not been revalidated or temperature mapped with adequate frequency. The <Redacted B4> last validation was approved in December 2016. During the December 2016 validation, there was signiicant variation in the temperature mapping profile. Biological indicators and endotoxin indicators were not in the <Redacted B4> areas during use.

Observation 10

Establishment of the reliability of the component supplier's report of analyses is deficient in that the test results are not appropriately validated at appropriate intervals.

Specifically, your firm has not adequately established the reliability of API and preservative supplier 's certificates of analyses. The qualification for three of three API or preservative suppliers reviewed do not include testing of any lots to ensure they meet the claims on the certificate of analyses provided by the supplier. The suppliers reviewed include suppliers of Methylcobalamin, Calcium Gluconate, Glutathione, and Benzol Alcohol. The Vendor Qualification procedure does not include testing to ensure API or preservative supplier certificate of analysis are accurate and representative of the product received.

AM ENDMENT2

Observation 11

Procedures for the cleaning and maintenance of equipment are deficient regarding the protection of clean equipment from contamination prior to use.

Specifically, utensils used to weight and containers that hold components are not stored adequately to prevent contamination. On 9/17/2019, I observed the utensils and containers in the ISO 8 environment without protection. The utensils and containers are used to hold ingredients prior to mixing. The items did not have maximum hold times.

Inspection Jul 9, 2018 to Aug 21, 2018: 10 observations

Firm on the cover
Auro Pharmacies, Inc. 520 W La Habra Blvd, CODE
FEI number
3011893599
Establishment type on the cover
La Habra, CA 90631-5308 Producer of sterile and non sterile drug products
FDA district office on the cover
Irvine, CA 92612-2445
Matched to this page by
FEI number on the cover; linked from Data Dashboard
FDA document
Read the full 483 (PDF on fda.gov)

This 483 is a scanned image. The text below is the PDF’s own text layer, which can misread characters; the PDF is the record.

Observation 1

The ISO 5 classified aseptic processing areas had visibly dirty equipment or surface.

Specifically, we observed apparent brown and white residue in the ISO 5 classified hoods that are used in the production of sterile drugs. You stated the hoods are cleaned <Redacted B4> production day. However, your firm was unaware ofthese observations until they were discussed on 07/09/2018 and subsequently on 07/18/2018. For example:

A. On 07/09/2018, we observed apparent brown residue on the HEPA filter of an JSO 5 classified <Redacted B4> la minar flow hood, identified as Hood #2. This hood is used in dispensing of sterile drug products. In addition, w e also observed apparent white residue on the <Redacted B4> surface, along with apparent brown res idue in one perforation of the,<Redacted B4>. Both the residue on the filter, and the <Redacted B4> are located on the c eiling directly above where sterile drug products are dispensed into final containers. This hood was last used to produce ''NAD TRIHYDRATE 250 MG VIAL LYOPHILIZED INJECTABLE", lot 180531@12 on 05/31/2018, RX K <Redacted B4>

B. ...

Read the full 483 (PDF on fda.gov)

Observation 2

You did not make adequate product evaluation and take remedial action where actionable microbial contamination was found to be present in the ISO 5 classified aseptic processing area during aseptic production.

Specifically, you had viable air monitoring samples above action levels <Redacted B4> consecutively in January, February and March of 2018 in ISO 5 hoods that are used in the production of sterile drugs. Your firm continued to produce sterile drugs without implementing a corrective and preventive action.

A. On 01/08/2018, your firm recovered l CFU/cubic meter from viable air samples collected from ISO 5 Hood #3 during production of"TESTOSTERONE CYPIONATE/ENANTHATE OIL INJECTION 126/54 MG/.ML INJECTABLE'', lot 180108@25, RX <Redacted B4>

B. On 02/28/2018, your third-party contractor recovered 1 CPU/cubic meter from viable air particle monitoring during routine preventive maintenance of the <Redact ed B4> laminar air flow ISO 5 classified Hood #2. This hood was used to produce "NAD TRIHYDRATE 250 MG/VlAL LYOPHILIZED INJECTABLE", lot 180430@16 on 04/30/2018, RX <Redacted B4>

C. ...

Read the full 483 (PDF on fda.gov)

Observation 3

Media fills were not performed that closely simulate aseptic production operations incorporating, as appropriate, worst-case activities and conditions that provide a challenge to aseptic operations.

Add Continuation Page

Specifically,

A. Your firm had two media fill failures on 10/06/2016 and subsequently on 03/08/2018. Your firm continued processing sterile products despite these two media fill failures. For example:

1. On I0/06/2016, a media fill batch was performed using <Redacted B4> mL vials in ISO 5 classified Hood #4. Of the <Redacted B4> vials filled, one vial resulted in microbial growth. After this media fill failure, your firm continued to produce sterile drugs without implementing corrective and preventive actions during a six-month time frame.

2. On 03/08/2018, a media fill batch was performed using <Redacted B4>mL vials in ISO 5 classified Hood #5. Of the <Redacted B4> vials filled, one vial resulted in microbial growth. After this media fill failure, your firm continued to produce sterile drug products without implementing corrective and preventative actions.

B. ...

Read the full 483 (PDF on fda.gov)

Observation 4

JS0-5 classified areas were not certified under dynamic conditions. Specifically, uni-directional airflow was not verified under operational conditions.

Specifically,

Your dynamic smoke study for ISO 5 classified Hood #2 and the ISO 5 <Redacted B4> , which demonstrates laminar airflow for the process of transferring vials from Hood #2 to your <Redacted B4> , is inadequate in that it is not representative of your process, and objects that block airflow over the vials were observed. Furthermore, the video you provided cannot be adequately evaluated. For example, in the video your provided:

A. No stoppers are present on the vials in the video you provided. Your process is to <Redacted B4> Ion vials as you transfer them from Hood #2 into the <Redacted B4>

B. You move vials <Redacted B4> as part of the process to transfer vials from Hood #2 to your <Redacted B4> While vials move <Redacted B4> IDuring this transfer, the flow of uni-directional air to the vials may be interrupted.

C. The amount of smoke present in the video is insufficient to visualize uni-directional airflow in the region of the vials.

Observation 5

Vermin was observed in an area immediately adjacent to your production area.

Add Continuation Page

Specifically,

On 07/09/2018 we observed:

A. Seven apparent ants along the floor wall-junction of the east wall; and on the north wall of the pre-gown room, identified as room 101. This room is where non-sterile hairnets and masks are donned. In addition, this room leads to the ISO 8 classified gowning room, where your operators don sterile gowns, hoods, and boots before entering the sterile suite.

Observation 6

Personnel conducted aseptic manipulations in an area that blocked the movement of first pass air around an open unit, either before or after it was filled with sterile product.

Specifically,

We observed a sterile technician using poor aseptic technique by placing his head and body into an ISO 5 classified <Redacted B4> laminar flow hood, identified as Hood #5, while dispensing a drug purporting to be sterile after performing the final <Redacted B4> step. The drug being dispensed was "TESTOSTERONE CYPIONATE/ ENANTHATE OIL INJECTION 160/40 MG/ML INJECTABLE", lot 180709@23.

Add Continuation Page

Observation 7

Each component is not tested for conformity with all appropriate written specifications fqr purity, strength, and quality.

Specifically, <Redacted B4> from your <Redacted B4> is used as an ingredient in the production of <Redacted B4> ., non-sterile drug products. Regarding this, the following issues were observed:

A. Your firm does not perform any microbial testing of the <Redacted B4> by your <Redacted B4> Additionally, your SOP, <Redacted B4> Operation, SOP-SC-01.1676.02, is deficient as the procedure does not require you to perform any microbial testing of the <Redacted B4> by you <Redacted B4>

B. Your SOP <Redacted B4> Operation, SOP-SC-01.1676.02, requires that <Redacted B4> and <Redacted B4> be monitored, yet from 03/08/2018 to 07/16/2018 your firm has only monitored <bH4> Your firm has not conducted any analytical <Redacted B4> testing of the <Redacted B4> through your <Redacted B4> between the dates 09/11/2017 and 03/08/2018. For example, "TETRACAINE HCL TOPICAL 2% SOLUTION", lot 180212@21, made on 02/12/20 18, RX <Redacted B4> , shows ' <Redacted B4> " was used as an ingredient.

C. The v<Redacted B4> used to <Redacted B4> has not been qualified and validated. ...

Read the full 483 (PDF on fda.gov)

Observation 8

The written stability testing program is not followed.

Add Continuation Page

Specifically,

Your firm has not conducted any stability studies to establish Beyond Use Dates (BUD) for your non-sterile drug products. For example, we observed: "TETRACAINE HCL TOPICAL 2% SOLUTION" oflot 180212@21, produced on 02/12/2018 where a BUD of 05/13/2018 was applied. You have no assurance that this BUD is appropriate.

This is a repeat observation from the 2015 FDA inspection.

Observation 9

You have not established appropriate Beyond Use Dates for your products.

You used stock solutions with 180 day (six-month) beyond use dates (BUD) as an ingredient in the production of sterile drug products. These following stock solutions were stored at room temperature in the ISO 7 classified clean room:

A.<Redacted B4> lot <Redacted B4> prepared on: 02/26/2018, BUD: 08/25/2018

B. 0<Redacted B4> , lot <Redacted B4> prepared on: 02/12/2018, BUD: 08/12/2018

These stock solutions were used in the production of"FOLIC ACID INJECTION BENZYL ALCOHOL 10 MG/ ML INJECTABLE", lot 180515@2 on 05/15/2018, <Redacted B4> , with BUD of 08/12/2018 at room temperature.

Observation 10

Buildings used in the manufacture, processing, packing, or holding o fa drug product do not have the suitable construction to facilitate cleaning, maintenance, and proper operations.

Specifically,

A. On 07/09/2018, we observed a gap, approximately 1/4 inch by 112 inch, under the south door that opens to a hallway leading to the unclassified pre-gown room.

B. On 07/18/2018, in the ISO 8 classified prep room, we observed a lack of backflow protection devices on the sink where municipal water and <Redacted B4> is supplied. Water from these supplies are used to wash equipment and utensils used in the production of sterile drug products; and <Redacted B4>

Add Continuation Page

Inspection Jun 29, 2017: 13 observations

Firm on the cover
Auro Pharmacies Inc, 511 S Harbor Blvd Ste F, La Habra, CA 90631 -9375
FEI number
3012228279
Establishment type on the cover
Outsourcing Facility
FDA district office on the cover
19701 Fairchild Irvine, CA 92612~2445
Matched to this page by
FEI number on the cover; linked from Data Dashboard
FDA document
Read the full 483 (PDF on fda.gov)

Observation 1

The responsibilities and procedures applicable to the quality control unit are not fully followed.

Specifically, the quality control unit does not, take full responsibility in ensuring that sterile drug products prepared by your firm .meet all the required specifications before release and that the firm's operations follow established standard operating procedures or approved documents. For example,

A. Methylcobalamin 1 mg/mL injection lot 170214@1 was tested at a contract lab <Redacted B4>, with active ingredient assay result of <Redacted B4>% which failed the specification of <Redacted B4>%. Even through the. associated investigation memo (OOS 00010) concluded that the lot was placed into quarantine and subsequently destroyed, the batch record was approved on 5/2/2017 for release and the product batch was distributed to customers.

B. Methylcobalamin 1 mg/mL injection lot 170310@1 was tested.at a contract lab, <Redacted B4> with active ingredient assay result of <Redacted B4>% which failed the specification of <Redacted B4> %. No OOS investigation was generated. The batch record was approved on 3/30/2017 for release and the product batch was distnbuted to customers.

C. ...

Read the full 483 (PDF on fda.gov)

Observation 2

The accuracy, sensitivity, specificity and reproducibility of test methods have not been established.

Specifically, the test methods used. to release your firm's sterile drug products are either not validated or verified for their intended use. For example,

A. Your firm's sterile drug products are sent to a contract lab, <Redacted B4> for assay test. According to <Redacted B4> certificate of analysis, most of the assay test procedures are not validated. Your firm used the test results from these non-validated procedures to release drug products . . B

. The Methylcobalamiµ 1 mg/m.L injection product lot 170214@l fai led assay test at <Redacted B4> with

a non-validated HPLC procedure (OOS-00010 ). Your firm retested the product lot in-house wi th an <R edacted B4> instrument and released the product lot based on the pass ing r esu lt s. This <Redacted B4> in-house test method was not established and not validated.

C. Your firm has conducted sterility, endotoxin, and particulate tests in-house to release the sterile

drug products since May 2017. None of these test methods used in-house have been validated or verified. ...

Read the full 483 (PDF on fda.gov)

Observation 3

Specifically, the gowning is not appropriate for the sterile filtration operation inside the clean room <Redacted B4>. For exa mple, ·

A. On 6/13/2017 during a walk through inspection, <Redacted B4> operators were observed. with partially exposed skin inside the ISO 7 clean room <Redacted B4>. The facial area around the eyes was not covered. Even though operators used goggles to cover the skin around eyes when working at the ISO 5 LFH, the goggles were put on when operators were inside the ISO 7 room <Redacted B4>. The operators were observed performing aseptic preparation of Magnesium Chloride drug product lot 170613@1 on that day, According to section 3.2.2.11 of SOP-SC-01.1300.02 Gowning and Gowning Certification effective 16-Dec-16, <Redacted B4>

B. The goggles used by operators during Magnesium Chloride drug product fot 170613@1- aseptic

preparation on 6/13/2017 were not sterile; Section 3.2.7 of SOP-SC-01.1300.02 states <Red acted B4>

Observation 4

Procedures designed to prevent microbiological contamination of drug products purporting to be sterile not established and followed.

are

Specifically, your firm's aseptic preparation of drug producds not appropriate. For example;

During a walk through inspection on 6/13/2017. an.operator was seen filling Magnesium Chloride drug product lot l 70612@1 <Redacted B4> inside the ISO 5 LPN. The operator <Redacted B4>

Observation 5

Procedures designed to prevent microbiological contamination of drug products purporting to be sterile do not include adequate validation of the sterilization process.

Specifically,

A. The ISO 5 LFH certification performed in February 2017 did not include active air viable count assessment.

B. The certification of all clean areas including ISO 5 LFHs and ISO 7 rooms performed in February 2017 were performed only at the <Redacted B4> condition.

C. Your firm does not perform active air monitoring during aseptic processing of drug product.

D. Your firm does not perform growth promotion tests for every batch of media <Redacted B4> th at were prepared in-house for environmental monitoring during sterile drug product preparation to ensure that the media used can support microbial g rowth. For example,. the following batches of <Redacted B4> media were not tested for growth p r o mo tion <Redacted B4> 1. Lot 170206/20 and lot 170124/21 used for environmental monitoring during the preparation of Methylcobalamin 1 mg/min injection product lot 170214@1. The product· lot was released on 5/2/2017. 2. ...

Read the full 483 (PDF on fda.gov)

Observation 6

Specifically the cleaning practice used in your firm's aseptic filling operation areas is not appropriate. For example,

A,. No sporicidal agent is used in the clean rooms other than inside the ISO 5 LFH.

B. The surface of equipment used for aseptic filling process inside ISO 5 LFH, such as peristaltic pump, wa:s never cleaned with sporicidal agent.

C. According to section 3.2 of SOP-SC-0L1305.Q2 Cleaning of Sterile Compounding Facil ity effective 9-December 16 <Redact ed B4

>. Ther e are at least 3 instances shown below Where the <Reda cted B4> cleaning on walls and ceilings was not performed. Sterile drug products were prepared during these weeks. No deviation investigation or justification was documented. 1. The week of 5/08/2017. The cleaning form was·approved. 2. The week of 5/I5/2017. The cleaning form was approved. 3. The week of 5/22/2017. The cleaning form. was not approved.

1. The week of 5/08/2017. The cleaning form was approved. 2. The week of5/IS/2017. The cleaning form_ was approved. 3. The week of 5/22/2017. The cleaning form was not approved.

Observation 7

Aseptic processing areas are deficient regarding the system for monitoring envionmental conditions.

Specifically,

E. Your firm's current environmental monitoring program does not include any viable and non-viable particulate monitoring during aseptic filling of drug product inside ISO 5 LFH.

F. Pressure differentials are monitored <Redacted B4> in the classified clean rooms., However such pressure differentials are not monitored at the time during aseptic filling of drug products,

G. Your firm takes <Redacted B4> from the IS0 5 LFH <Redacted B4> as part of the <Redacted B4> EM monitoring. No justification is established on why no other surface samples are taken from the inner walls of the IS0 5 LFH.

H. Your firm has no justification for the alert and action limits established for environmental monitoring. This deficiency was cited during the last FDA inspection. For example, alert and action limits for settling plates used during aseptic fillmg of drug product in ISO 5 LFH are set incorrectly at <Redacted B4> CFU/P late and <Redacted B4> CF U/Plate respectively. ...

Read the full 483 (PDF on fda.gov)

Observation 8

The flow of drug product containers and closures though the building is not designed to prevent contamination.

Specifically, the vials and stoppers used for your firm's sterile products are not cleaned appropriately before being depyrogenated or sterilized. For example,

A. The vials were washed in a non-classified room <Redacted B4>. On 6/13/2017 during a walk through inspection, the door to room <Redacted B4> was widely open and employees working inside the room <Redacted B4> were seen wearing street shoes.

B. According to section 3.1 of SOP-SC-01.1620.01 Vial Washer <Redacted B 4> effe ctive 22 ­August-16 the wash machine requires <Redacted B4> of air pressure and <Redacted B4> of <Redacted B4> at the inlet. However water was-used by yout firm to operate the wash machine for vials. Your firm's <Redacted B4> system has not been operational yet at the time of this inspection. Vials washed by this machine are used for all sterile drug products prepared by your firm.

However~ ittiff•· water was-used by yout firm to operate the wash machine for vials. Your firm's .

(b)l4) system has not been.operational yet at the time ofthis .inspecticm. ...

Read the full 483 (PDF on fda.gov)

Observation 9

Testing and release of drug product for distribution do not include appropriate laboratory determination of satisfactory conformance to the final specifications prior to release.

Specifically, your firm's 100% visual inspection of the finished drug product vials is inadequate . Fo r example ,

A. There is no written procedure describing the process for 100% visual inspection of filled drug product vials. This deficiency was cited from .the last FDA inspection.

B. O n 6/13/2017 during a walk through inspection at the product labeling room, an operator wa s se

en performing visual inspection of the filled Amino Syn 10% drug product lot 170523@2 by < Redacted B4> to inspection. There is no documented training record for thi s operator on the 100% visual drug product inspection . This deficiency was cited from the las t FDA inspection .

C. According to the batch records, your firm did not perform 100% visual inspection of the filled drug product vials. The field for 100% visual insoection of finished drug product vials were either marked N/A or the field is not available from the master batch record. ...

Read the full 483 (PDF on fda.gov)

Observation 10

Written.records are not always made ofinvestigations into unexplained discrepancies and the failure of a batch or any. of its components to meet specifications. ·

Specifically, your firm failed to initiate OOS investigations into EM failures associated with drug product preparation or failed to conduct thorough investigations to understand the root causes ofsome of the product testing result failures. For example,

A .. Your firm failed to conduct thorough investigations on the product assay failures associated with the finished products,

l. The assay result of Procaine HCl 10 gm/mL injection product lot 170131@1 was reported as <Redacted B4> % which exceeded the specification <Redacted B4> % and the failure result was confirmed by the contract testing lab, <Redacted B4> as shown in OOS report 0003. No detailed manufacturing investigation was earned out to identify the possible root causes. The lot was destroyed.

2. The assay result of Glutamine 30 mg/mL injection product lot 170221@2 was reported as <Redacted B4>% which failed the specification <Redacted B4> % as shown in OOS report 0007. No detailed manufacturing investigation was carried out to identify the possible root causes. ...

Read the full 483 (PDF on fda.gov)

Observation 11

Investigations of an unexplained discrepancy and a failure of a batch or any of its components to meet any of its specifications did not extend to other batches of the same drug product and other drug products that may have been associated with the specific failure or discrepancy.

Specifically, the investigation documented in NCR-17-0020 for Methylcobalamin 2 mg(mL injection product lot 170501@2 recognized that the assay test procedure for the.product used.by the contract lab, <Redacted B4>, was not validated. However the investigation failed to extend the evaluation of assay test procedures used by <Redacted B4> to your firm's other drug products. lt appeared that most of the assay test procedures used by <Redacted B4> on the firm's finished drug products were not validated as shown on <Redacted B4> certificate of analyses. No corrective actions have been taken by your firm to address this deficiency at the time of this inspection.

t

Observation 12

Results of stability testing are not used in determining expiration dates.

Specifically. the shelf life of your firm's products is not supported by stability studies. For example,

A. All sterile drug products prepared by your firm are assigned a 6 month shelf life. There is no stability study carried out on each drug product to demonstrate that the products can maintain their identity, strength, quality, and purity at the end of the shelf life.

B. The <Redacted B4> on-going product stability studies for Ascorbic Acid 500 mg/mL injection with preservative and Glutathione 200 mg/mL injection without preservative are deficient in that

1. These studies were initiated without approved stability study protocols.

2. The studies did not follow the written study protocols with respect to storage conditions and test frequency.

3. The analytical methods used for the stability studies at contract lab, <Redacted B4> are not validated to demonstrate that they are stability indicating.

Observation 13

Laboratory controls do not include the establishment of scientifically sound and appropriate specifications, sampling plans and. test procedures designed to assure that drug products conform to appropriate standards of identity, strength, quality and purity.

Specifically,

A. The preservative content in your sterile drug products was not determined as part of product release testing.

B. You have not demonstrated the effectiveness of the antimicrobial preservative ingredient used i

n your sterile drug products . According to section 3.2 of SOP-SC-01.1340.01 Antimicrobi al Effectiveness Testing, effective 29-Jul-16, <Red acted B4>

~0)(4)

b)(4)

Inspection Nov 1, 2016 to Dec 2, 2016: 16 observations

Firm on the cover
, 511 S Harbor Blvd Ste F Auro Phar maci es I nc
FEI number
3012228279
Establishment type on the cover
Outsourcing Facility La Habra, CA 90631- 9375
FDA district office on the cover
Irvine, CA 92612-2445
Matched to this page by
FEI number on the cover; linked from Data Dashboard
FDA document
Read the full 483 (PDF on fda.gov)

This 483 is a scanned image. The text below is the PDF’s own text layer, which can misread characters; the PDF is the record.

Observation 1

Procedures designed to prevent microbiological contamination of drug products purporting to be sterile do not include adequate validation of the sterilization process.

Specifically,

A. The process simulations conducted by your firm on r edacted (b)(4) are inad equa te and do not rep rese nt the ac tually manufac turing operations of Ascorbi c Acid 500 mg/ ml. For example:

1) The process simulations were conducted using redacted (b)(4).

2) The inspection process of the process simulations vials are not described in the SOP-SC-

01.1365.01, "Aseptic Media Filling Procedure" and process simulation protocol. Your firm indicated that redacted (b)(4) redact ed (b)( 4) be fore they are redacted (b)(4). ~

3) Growth promotion conducted for incubated vials are inadequate in that unknown amounts of organisms were used for the growth promotion. Your firm conducted the growth promotion of the incubated vials by using redacted ( b)(4) to inoculate the vials.

AMENDMENT 1

4) The process simulations do not represent actual production filling batch size. Operators filled redacte d (b)(4) bat ches for the process simu lati ons. The manu factured Ascor bic Acid 500 mg/ml ba tch es are redacted (b)(4). ...

Read the full 483 (PDF on fda.gov)

Observation 2

Aseptic processing areas are deficient regarding the system for monitoring environmental conditions.

Specifically,

A. Your firm has not performed qualification of the Room redacted (b)(4) to demonstrate that ISO 5 and ISO 7 environmental conditions c an be met. For example, your firm does not conduct viab le and non-viable monitoring in dynamic conditions.

B. Your firm does not have a justification or rational to support the sampling sites used for monitoring the environment during aseptic filling operation.

C. Your firm's current environmental monitoring program does not include any non-viable

particulate monitoring during filling of sterile drug product.

D. Your firm's monitoring of the pressure differentials throughout the classified areas where aseptic filling occurs is inadequate. Room pressure is monitored redacted (b)(4) the

ed acted (b)(4). Pressure differentials are not monitored during aseptic filling o f the product manufactured which does not assure notification of a disruption in established pre ssure cascade for a prolonged duration which could impact the classified areas.

r

F.. ...

Read the full 483 (PDF on fda.gov)

Observation 3

AMENDMENT 1

Time limits are not established when appropriate for the completion of each production phase to assure the quality of the drug product.

Specifically,

Your firm does not have a hold time study to support the redacted (b)(4). This lot was compounded and redacted (b)(4). Bioburden was not performed prior to redacted (b)(4). Your firm does not have a hold time study to support the redacted (b)(4). This lot was compounded and redacted (b)(4). Bioburden was not performed prior to redacted (b)(4). Your firm does not have a hold time study to support the redacted (b)(4). This lot was compounded and redacted (b)(4). Bioburden was not performed prior to redacted (b)(4). Y our firm does not have a hold time s tu dy to suppor t th e re dacted (b)(4). This lot was compounded and redacted (b)(4). Bioburden was not performed prior to redacted (b)(4).

Observation 4

Clothing of personnel engaged in the manufacturing, processing, packing and holding of drug products

is not appropriate for the duties they perform.

Specifically,

A. On 11/02/2016, aseptic fill p rocess support staffs with exposed eye area were observed to have p laced their face d irectly i n front of the ISO 5 l aminar flow hood during the f illing p rocess of A scorbic Acid 500 mg/ml lot # 161102@1 .

B. On 11/02/2016, one aseptic fill process support staff with exposed eye area was observed reaching inside and place reda cted (b)(6), ( b)(7) ( C) f ac e in front of the ISO 5 l amin ar flow hood during the filling process of Asco rbic Acid 500mg/ml lot # 16102@1.

C. On 11/10/2016, redacted (b)(4) operators with exposed eye area were observed placing their faces in

front of the ISO 5 laminar flow hood during the cleaning process.

D. On 11/01/2016, one operator with exposed eye area was observed placing redacted (b)(6) (b)(7) (C) head inside the ISO 5 laminar flow hood during the cleaning process. On 11/01/2016, one operator with exposed eye area was observed placing redacted (b)(6) (b)(7) (C) head inside the ISO 5 laminar flow hood during the cleaning process. ...

Read the full 483 (PDF on fda.gov)

Observation 5

Approved components, drug product containers and closures are not retested or reexamined as appropriate for identity, strength, quality and purity after exposure to conditions that might have an adverse effect with subsequent approval or rejection by the quality control unit.

Specifically, your firm does not have adequate control over equipment and closures to maintain their sterility. For example,

A. Your firm does not have a study to show the adequacy and sterility of the redacted (b)(4). For example, the redacted (b)(4), redacted (b)(4), and redacted (b)(4) at the redacted (b)(4). The redacted (b)(4 are then redacted (b)(4) redacted (b)(4) for used in Ascorbic Acid 500mg/ml Lot# 161026@1, 161028@l, and 161102@1. Additionally, the redacted (b)(4) procedure, SOP-SC-01.1390.01, redacted (b)(4), stated that redacted (b)(4) to be recorded on the redacted (b)(4) log. Your firm did not fill the log until 11/01/16. These stoppers were used in Ascorbic Acid 500mg/ml Lot# 161102@1.

Your firm does not have a study to show the adequacy and sterility of the redacted (b)(4). For example, the redacted (b)(4), redacted (b)(4), and redacted (b)(4) at the redacted (b)(4). ...

Read the full 483 (PDF on fda.gov)

Observation 6

Aseptic processing areas are deficient regarding the system for cleaning and disinfecting the room and equipment to produce aseptic conditions.

Specifically,

A. No sporicidal agent used in the ISO 5 Laminar Flow Hood where aseptic filling occurs.

B. Your firm re-uses old sterile redacted (b)(4) bott les to refil l with new re da cted (b)(4) re dacted (b)(4) from a bulk container with no assurance of sterility and documenting

new lot numb er of t he redac ted (b)(4) o n the bottle. On 11/1/16, a t echnici an was observe d to refill an old bottle of redacted (b)(4) redacted (b)(4) with redacted (b)(4) from a bulk one gallon bottle from redacted (b)(4) that was used to clean the ISO 5, ISO 7 and ISO 8 areas.

AMENOMENT 1

[(b) (4) ~b)(4) j with ~b ) (4) J from a bulk one gallon bottle from[b) (4) that was used to clean the ISO 5, ISO 7 and ISO 8 areas.

Observation 7

Written records are not always made of investigations into unexplained discrepancies.

Specifically,

A. Your firm failed to investigate action level excursion involving personnel monitoring of the redacte

d (b)(4) for operator redacted (b)(6),(b)(7)(C) during an aseptic filling of the product on 10/28/16. The documented action level is redacted (b)(4) 7 CFUs was reported for operator redacted (b)(6),(b)(7)(C).

Your firm failed to investigate action level excursion involving personnel monitoring of the redacted (b)(4) for operator redacted (b)(6),(b)(7)(C) during an aseptic filling of the product on 10/28/16. The documented action level is redacted (b)(4) 7 CFUs was reported for operator redacted (b)(6),(b)(7)(C).

Your firm failed to investigate action level excursion involving personnel monitoring of the redacted (b)(4) for operator redacted (b)(6),(b)(7)(C) during an aseptic filling of the product on 10/28/16. The documented action level is redacted (b)(4) 7 CFUs was reported for operator redacted (b)(6),(b)(7)(C). ...

Read the full 483 (PDF on fda.gov)

Observation 8

Laboratory controls do not include the establishment of scientifically sound and appropriate sampling plans and test procedures designed to assure that drug products conform to appropriate standards of identity, strength, quality and purity.

Specifically,

Your firm does not perform growth promotion testing of new batches of media redacted ( b)(4) that were red acted (b)(4) for use in media fill and environmental monitoring to ensure that the media used can support microbiological growth.

Observation 9

AMENDM ENT 1

Each batch of drug product purporting to be is not laboratory tested to determine conformance to such requirements.

Specifically,

Suitability testing for the sterility test method necessary to demonstrate that the product does not interfere with the test, has not been performed by the contract testing laboratory which conducts the release testing of the product made.

Observation 10

There is no written testing program designed to assess the stability characteristics of drug products.

Specifically,

Your firm could not provide the supporting data including batch worksheet and drug substance supplier for the Ascorbic Acid redacted (b)(4) lot # redacted (b)(4) that is used to support the 180 days expiration date. The stability study was started on redacted (b)(4) with Ascorbic Acid redacted (b)(4) lot #redacted (b)(4). No comparison can be made for the Ascorbic Acid redacted (b)(4) lot # redacted (b)(4) to the formulation, drug substance, and container closure redacted (b)(4) to ensure that they are the same.

Your firm could not provide the supporting data including batch worksheet and drug substance supplier for the Ascorbic Acid redacted (b)(4) lot # redacted (b)(4) that is used to support the 180 days expiration date. The stability study was started on redacted (b)(4) with Ascorbic Acid redacted (b)(4) lot #redacted (b)(4). No comparison can be made for the Ascorbic Acid redacted (b)(4) lot # redacted (b)(4) to the formulation, drug substance, and container closure redacted (b)(4) to ensure that they are the same. ...

Read the full 483 (PDF on fda.gov)

Observation 11

Testing and release of drug product for distribution do not include appropriate laboratory determination of satisfactory conformance to the finall specifications prior to release.

AM ENDM ENT 1

Specifically, your firm's 100% visual inspection of the finished product vials is inadequate. For example,

A. There is no written procedure describing the process for 100% visual inspection of filled vials.

B. No formal training process for the visual inspectors to ensure that inspectors are provided with adequate training to perform the inspection process.

C. No qualification process for the visual inspectors to ensure that they are properly qualified to perform the inspection process. The finished sterile drug product vials are amber.

Observation 12

Container closure systems do not provide adequate protection against foreseeable external factors in storage and use that can cause deterioration or contamination of the drug product.

Specifically,

Your firm does not have container closure study for the container and closure used for Ascorbic Acid 500 mg/ml. Your firm's management indicated that study was performed but unable to locate the study supporting documents and data.

Observation 13

Drug product containers and closures were not clean and sterilized and processed to remove pyrogenic properties to assure that they are suitable for their intended use.

Specifically,

AMENDMENT 1

Observation 14

The quality control unit lacks authority to review production records to assure that no errors have occurred.

Specifically,

Your firm failed to thoroughly complete and review the qualification documents for the redacted (b ) (4) and r ed acted (b)(4). Your firm provided the following do cuments and indicated that they we re the final reports for the qualific ation of the liste d equipment. Ho wever, these documents have not been completed and reviewed prior to use for processing components, v ials, rubber stoppers, and utensils in the Ascorbic Acid 5 00 mg/ml Lot# 16102 6@1, 161028@1, and 161102@1.

• Document VAL-SC-05.5002.01, redacted (b) (4) Eq uipment Instal lation, Oper at ional & Performance Qualification AN 0530. Qualification was started on 04/06/16 and the last run was completed on 04/11/16.

• Document VAL-SC-05.5004.01 redacted (b) (4) Equipment installation, Operati onal and Performance Qualification AN 0042. Qualification was started on 04/15/16 and the last run was completed on 05/11/16.

• Document VAL-SC-05.5003.01 , redacted (b) (4) Eq uipment Instal lation, Operat ional & Performance Qualification A N 0550. ...

Read the full 483 (PDF on fda.gov)

Observation 15

There is a lack of written procedures describing in sufficient detail the receipt, identification, storage, handling, sampling, examination and testing of labeling and packaging materials.

Specifically,

Your firm does not have a written procedure describing the receipt, identification, storage, handling, sampling, and examination of labeling and packaging materials.

Observation 16

Procedures designed to assure that correct labels, labeling and packaging materials are used for drug products are not written.

Specifically,

Your firm does not have a written procedure describing the labeling operations of finished drug products.

Inspection Nov 1, 2016 to Dec 2, 2016: 16 observations

Firm on the cover
Auro Pharmacies Inc 511 S Harbor Blvd Ste F
FEI number
3012228279
Establishment type on the cover
Outsourcing Facility La Habra, CA 90631- 9375
FDA district office on the cover
19701 Fairchil d Irvine, CA 92612- 2445
Matched to this page by
FEI number on the cover; linked from Data Dashboard
FDA document
Read the full 483 (PDF on fda.gov)

This 483 is a scanned image. The text below is the PDF’s own text layer, which can misread characters; the PDF is the record.

Observation 1

Procedures designed to prevent microbiological contamination of drug products purporting to be sterile do not include adequate validation of the sterilization process.

Specifically,

A. The process simulations conducted by your firm on redacted (b)( 4) are inadequate and do not represent the actually manufacturing operations of Ascorbic Acid 500mg/ml. For example:

1) 1) The process simulations were conducted using redacted (b)(4)

2) 2) The inspection process of the process simulations vials are not described in the SOP-SC-01.1365.01, "Aseptic Media Filling Procedure" and process simulation protocol. Your firm indicated that redacted (b)(4) redacted (b)(4) before they are redacted (b)(4)

3) 3) Growth promotion conducted for incubated vials are inadequate in that unknown amounts of organisms were used for the growth promotion. Your firm conducted the growth promotion ofthe incubated vials by using redacted (b)(4) to inoculate the vials.

4) 4) The process simulations do not represent actual production filling batch size. Operators filled redacted (b)(4) batches for the process simulations. The manufactured Ascorbic Acid 500mg/ml batches are redacted (b)(4) ...

Read the full 483 (PDF on fda.gov)

Observation 2

Aseptic processing areas are deficient regarding the system for monitoring environmental conditions.

Specifically,

A. Your firm has not performed qualification of the Room redacte d (b) (4) to demonstrate that ISO 5 and ISO 7 environmental conditions ca n be met. For example, your firm does not conduct viabl

e and non-viable monitoring in dynamic conditions.

B. Your firm does not have a justification or rational to support the sampling sites used for

monitoring the environment during aseptic filling operation.

C. Your firm's current environmental monitoring program does not include any non-viable particulate monitoring during filling of sterile drug product.

D. Your firm's monitoring of the pressure differentials throughout the classified areas where aseptic

filling occurs is inadequate. Room pressure is monitored r edacte d

(b)(4) the redacted (b)(4). Pressure differentials are not monitored during aseptic filling of the product manufactured which does not assure notification of a disruption in established pressure cascade for a prolonged duration which could impact the classified areas.

!. ...

Read the full 483 (PDF on fda.gov)

Observation 3

Specifically,

Your firm does not have a hold time study to support the redacted (b)(4). This lot was compounded and redacted (b)(4). Bioburden was not performed prior to redacted (b)(4). Your firm does not have a hold time study to support the redacted (b)(4). This lot was compounded and redacted (b)(4). Bioburden was not performed prior to redacted (b)(4). Your firm does not have a hold time study to support the redacted (b)(4). This lot was compounded and redacted (b)(4). Bioburden was not performed prior to redacted (b)(4). Your firm does not have a hold time study to support the redacted (b)(4). This lot was compounded and redacted (b)(4). Bioburden was not performed prior to redacted (b)(4). Your firm does not have a hold time

st udy to sup port the redacted (b)(4). This lot was compounded and redacted (b)(4). Bioburden was not performed prior to redacted (b)(4). J

Observation 4

Clothing of personnel engaged in the manufacturing, processing, packing and holding of drug products is not appropriate for the duties they perform.

Specifically,

A. On 11/02/2016, aseptic fill process support staffs with exposed eye area were observed to have placed their face directly in front of the ISO 5 laminar flow hood during the filling process of Ascorbic Acid 500mg/mllot # 161102@1.

B. On 11/02/2016, one aseptic fill process support staff with exposed eye area was observed reaching inside and place red acted (b)(6), (b)(7) (C) fa ce in front o f the ISO 5 laminar flow hood during the filling process of Ascorbic Acid 500mg/ml lot # 161102@1.

C. On 11 /01 /2016 redacted (b) (4) operators with exposed eye area were observed placing their faces in front of the ISO 5 laminar flow hood during the cleaning process. On 11/01/2016 redacted (b) (4) operators with exposed eye area were observ ed placing their faces in front of the ISO 5 laminar flow hood during the cleaning process. On 11/01/2016 redacted (b) (4) operators with exposed eye area were observed placing their faces in front of the ISO 5 laminar flow hood during the cleaning process. ...

Read the full 483 (PDF on fda.gov)

Observation 5

Approved components, drug product containers and closures are not retested or reexamined as appropriate for identity, strength, quality and purity after exposure to conditions that might have an adverse effect with subsequent approval or rejection by the quality control unit.

Specifically, your firm does not have adequate control over equipment and closures to maintain their sterility. For example,

A. Your firm does not have a study to show the adequacy and sterility of the redacted (b)(4) redacted (b)(4). For example, the redacted (b)(4), and redacted(b)(4) at the redacted (b)(4)· The redacted (b)(4) are then redacted (b)(4) redacted (b)(4) for used in Ascorbic Acid 500mg/ml Lot# 161026@1, 161028@1, and 161102@1. Additionally, the redacted (b)(4) procedure, SOP-SC-01.1390.01, redacted (b)(4), stated that redacted (b)(4) to be recorded on the redacted (b)(4). Your firm did not fill the log until 11/01/16. These stoppers were used in Ascorbic Acid 500mg/ml Lot# 161102@1. r Yo ur firm d oe

s not have a study to show the adequacy and sterility of the redacted (b)(4) redacted (b)(4). ...

Read the full 483 (PDF on fda.gov)

Observation 6

Aseptic processing areas are deficient regarding the system for cleaning and disinfecting the room and equipment to produce aseptic conditions.

Specifically,

A. No sporicidal agent used in the ISO 5 Laminar Flow Hood where aseptic filling occurs.

B. Your firm re-uses old sterile redacted (b)(4) bottl es to r efill with new red acted (b) (4) redacted (b)(4) from a bulk container with no assurance of sterility and documentin

g new lot numbe r of the red act ed (b)(4) o n the bottl e. O n 11/1/16 , a techni cian was obser ved to refill an old bottle of redacted (b)(4) redacted (b)(4) with redacted (b)(4) from a bulk one gallon bottle from redacted (b)(4) that was used to clean the ISO 5, ISO 7 and ISO 8 areas.

Observation 7

Written records are not always made of investigations into unexplained discrepancies.

Specifically,

A. Your firm failed to investigate action level excursion involving personnel monitoring of the redacted (b)(4) for operator redacted (b)(6), (b)(7) (C) during an aseptic filling of the product on 11/28/16. The documented action level is redacted (b)(4) 7 CFUs was reported for operator (b)(6), (b)(7) (C). ~

Yo ur firm failed to inv estigate action level excursion involving personnel m onitoring of th e redacted (b)(4) for o perator redacted (b)(6), (b)(7) (C) during an aseptic filling of the product on 11/28/16. The documented action level is redacted (b)(4) 7 CFUs was reported for operator (b)(6), (b)(7) (C).

B. Your firm failed to investigate several action level excursions involving viable particulate monitoring during operation of ISO 7 and ISO 8 rooms.

1) 1) On redacted (b)(4), an action level excursion of TMTC (Too many to count) was found in Room (redacted (b)(4) Room), however an investigation or follow up was not conducted. ...

Read the full 483 (PDF on fda.gov)

Observation 8

Laboratory controls do not include the establishment of scientifically sound and appropriate sampling plans and test procedures designed to assure that drug products conform to appropriate standards of identity, strength, quality and purity.

Specifically,

Your firm does not perform growth promotion testing of new batches of media redacted (b )(4) that were red acted (b) (4) for use in media fill and environmental monitoring to ensure that the media used can support microbiological growth.

Observation 9

Specifically,

Suitability testing for the sterility test method necessary to demonstrate that the product does not interfere with the test, has not been performed by the contract testing laboratory which conducts the release testing of the product made.

Observation 10

There is no written testing program designed to assess the stability characteristics of drug products.

S pecifi call y,

Your firm could not provide the supporting data including batch worksheet and drug substance supplier for the Ascorbic Acid redacted (b)(4) lot# redacted (b)(4) that is used to support the 180 days expiratio n date. Th e stab ilit y study was started on red acted (b) (4) wi th As corb ic Acid redacte d (b)(4) lo t # red acted (b) (4). No compa rison can be made f or the A sco rbic Acid redacte d (b) (4) lot # r edac ted (b)(4) to the formulatio n, drug substance, and container closure redacted (b)(4) to ensure that they are the same.

Observation 11

Testing and release of drug product for distribution do not include appropriate laboratory determination of satisfactory conformance to the final specifications prior to release.

Specifically, your firm's 100% visual inspection of the finished product vials is inadequate. For example,

A. There is no written procedure describing the process for 1 00% visual inspection of filled vials.

B. No formal training process for the visual inspectors to ensure that inspectors are provided with adequate training to perform the inspection process.

C. No qualification process for the visual inspectors to ensure that they are properly qualified to perform the inspection process. The finished sterile drug product vials are amber.

Observation 12

Container closure systems do not provide adequate protection against foreseeable external factors in storage and use that can cause deterioration or contamination of the drug product.

Specifically,

Your firm does not have container closure study for the container and closure used for Ascorbic Acid 500 mg/ml. Your firm's management indicated that study was performed but unable to locate the study supporting documents and data.

Observation 13

Drug product containers and closures were not clean and sterilized and processed to remove pyrogenic properties to assure that they are suitable for their intended use.

Specifically,

Observation 14

The quality control unit lacks authority to review production records to assure that no errors have occurred.

Specifically,

Your firm failed to thoroughly complete and review the qualification documents for the redacted (b) (4) and r ed act ed (b)(4)· Your firm provided the following doc uments and indicated that they wer e the fmal reports for the qualification of the listed equipment. Howe ver, these documents have not been completed and reviewed prior to use for processing components, via ls, rubber stoppers, and utensils in the Ascorbic Acid 500 mg/ml L ot# 161026@1, 161028@1, and 161102@1.

• Document VAL-SC-05.5002.01 redacted (b)(4) Equ ipment Install ation, Opera ti onal & Performance Qualification AN 0530. Qualification was started on 04/06/16 and the last r un was completed on 04/11/16.

• Document VAL-SC-05.5004.01 redacted (b)(4) Equipment Installation, Operational and Performance Qualification AN 0042. Qualification was started on 04/15/16 and the last run was completed on 05/ll/16.

• Document VAL-SC-05.5003.01. redacted ( b) (4) Equip ment Installat ion, Operati on al & Performance Qualification AN 0 550. ...

Read the full 483 (PDF on fda.gov)

Observation 15

There is a lack of written procedures describing in sufficient detail the receipt, identification, storage,

handling, sampling, examination and testing of labeling and packaging materials.

Specifically,

Your firm does not have a written procedure describing the receipt, identification, storage, handling, sampling, and examination of labeling and packaging materials.

Observation 16

Procedures designed to assure that correct labels, labeling and packaging materials are used for drug products are not written.

Specifically,

Your firm does not have a written procedure describing the labeling operations of finished drug products.

Earlier Form 483s

The text of every observation in these is in the form-483-observations.csv download.

State board of pharmacy records

No license with this exact name and city was found in the California State Board of Pharmacy file dated Nov 6, 2026. A pharmacy can hold its license under a different legal name, so this is not a finding that it is unlicensed. The file lists current licenses only, not revoked, surrendered or cancelled ones. Board file.

Board actions

As the board words them, newest first. An entry that is a complaint, charge or notice the board filed is a charge, not a final decision; only an order or final action records the outcome.

What this covers: Facility license decisions from the board’s quarterly Disciplinary Actions pages (87 of 88 quarters had a facility section). These are final decisions; accusations filed and immediate protection orders are not included. Actions in the data are dated Jan 5, 2005 to Oct 28, 2026.

Nonresident licenses in other states

These boards list a nonresident license whose record names this pharmacy’s own name, city and state.

Colorado State Board of Pharmacy, file dated Nov 15, 2026 (Colorado).

LicenseType as the board gives itName on the board recordLocationStatus
OSP 5808OSPAuro Pharmacies, Inc. DBA Central DrugsLa Habra, CAActive

Illinois Department of Financial and Professional Regulation, file dated Nov 13, 2026 (Illinois).

LicenseType as the board gives itName on the board recordLocationStatus
054018330LICENSED PHARMACYAURO PHARMACIES INCLA HABRA, CAACTIVE

Connecticut Department of Consumer Protection, file dated Nov 15, 2026 (Connecticut).

LicenseType as the board gives itName on the board recordLocationStatus
PCN.0002978NONRESIDENT PHARMACYAURO PHARMACIES INC (dba CENTRAL DRUGS)LA HABRA, CAACTIVE (CURRENT)

This page restates FDA’s lists and state board of pharmacy records. A Form 483, letter or board action is not a finding by this site, and a missing record is not a finding either way. A state license is matched only on the same name, city and state. Follow each link for the original document. Report an error or add a company response.

Sources

Records last pulled Nov 15, 2026. Every entry links to the original public record.